Security key
G2545C104
CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share (CBIO)
CUSIP: G2545C104
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Ordinary Shares, $0.001 par value per share
- Total 13F shares
- 50,824
- Total 13F value
- $914,832
- Share change
- +50,824
- SEC-reported price per share
- $18.00
- Number of holders
- 1
- Value change
- +$914,832
- Number of buys
- 1
- Shares outstanding
- 27,553,444
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
CBIO full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
CRESCENT BIOPHARMA, INC. SEC filings
CRESCENT BIOPHARMA, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP G2545C104
Recent filing periods:
Ownership snapshot
Top reported holders of CBIO - CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 19%
13D/G row: Fairmount Funds Management LLC
Showing 1-6 of 15 holder rows.
Quick read
Fairmount Funds Management LLC leads the comparable SEC ownership view at 19%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership
Top 5
Fairmount Funds Management LLC
19%
FMR LLC
15%
1Globe Capital LLC
10%
BIOTECHNOLOGY VALUE FUND L P
10%
Venrock Healthcare Capital Partne...
9.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
19%
|
$73,252,396
5,643,482 shares
|
+$32,700,021 | 04 Dec 2025 |
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$75,932,653
4,133,514 shares
|
— | 31 Mar 2026 |
| 1Globe Capital LLC |
13D/G
|
10%
|
$20,839,816
1,425,432 shares
|
+$7,729,886 | 07 Oct 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$18,736,150
1,387,863 shares
|
$0 | 30 Jun 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
9.5%
|
$29,460,007
2,666,064 shares
|
$0 | 31 Dec 2025 |
| ForGrowth III PA B.V. |
13D/G
|
6.1%
|
$21,778,519
1,677,852 shares
|
$0 | 08 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
50,824
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
59
Q2 2026 holders
1
Holder diff
-58
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend